[ad_1]
Against the coronavirus epidemic in Germany There has been another hopeful development. State Television ARD announced that following the corona virus vaccination, a drug has been developed that will continue the normal treatment process. Formycon, the biotech company that developed the drug, made the necessary applications for emergency use.
This drug has been a great hope for those who cannot be vaccinated, become ill again after vaccination, or do not produce antibodies and need to be treated with medications for various reasons. The Fromycon company is located in Planegg-Martinsried, near Munich. The drug completely blocks Covid 19 (SARS CoV-2).
Effective if mutated
The developed drug completely prevents cells from becoming infected with this virus and uses the ACE2 receptors that the virus uses to enter the body, while the drug is effective exactly where the ACE2 antibody fusion protein comes from, which binds effectively to corona viruses. In a sense, it closes the doors of arrival of the corona virus. The drug was announced to be effective against the mutated version of the virus as well.
Fromycon CEO Carsten Brockmeyer told the ARD television newsletter “tagesschau” that people who are now hospitalized have a treatment option. Later it was found that drugs like Remdesivir, which had been applied until now, did not work at all and the lack of a complete treatment method had very negative consequences in seriously ill patients.
THE RESULTS WILL NOW BE AVOIDED
Brockmeyer stated that the drug is the solution at this stage, saying: “Antibodies target very specific areas on the surface of the SARS CoV-2 virus. However, a small mutation of the virus is enough to neutralize them. With this drug, we block the door of entry that the virus uses to enter cells. This provides maximum protection against mutations. “This will prevent future outbreaks of the corona virus,” he said.
EARLY 2022
The company that developed the drug announced that it has contacted the US drug approval center and the European Union approval center and that the process has been carried out for speedy approval. However, even faster approval indicates that they will be able to launch the drug only in early 2022.
ARD’s “Isn’t it too late then?” Brochmeyer said: “It will take years to vaccinate 50 to 60 percent of the world’s population. Even after 10 years, there will be millions of people who have not been vaccinated and will contract this disease again even if they get vaccinated. There is currently no other option to treat these people. “If we reduce the rate of illnesses with drugs, most of the threat from the virus will disappear,” he replied.
It may interest you
It may interest you
[ad_2]
